Coya Therapeutics plans open-label extension of Phase 2/3 ALSTARS trial of COYA 302 in ALS
COYA•Coya Therapeutics expects to start an open-label extension of its Phase 2/3 ALSTARS trial in November 2026 to collect longer-term safety and efficacy information. It delayed a planned Phase 2 study of COYA 302 in frontotemporal dementia to 2027 from the second half of 2026; cash runway guidance is unchanged, with funds expected to last into the second half of 2027.
1. Extension and study timing
Coya Therapeutics plans an open-label extension of its Phase 2/3 ALSTARS trial of COYA 302 in ALS, with a start expected in November 2026 as the first cohort completes treatment. The extension will collect longer-term safety and efficacy information beyond the 48-week period; no clinical results were reported. The company said investigator and participant requests to continue dosing drove the plan. A planned Phase 2 study of COYA 302 in frontotemporal dementia is delayed to 2027 from the second half of 2026, while cash runway guidance remains unchanged, with existing cash expected to fund operations into the second half of 2027.
